Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Completed · Phase 3

Conditions studied: Psoriatic Arthritis

In brief

This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).

Key facts

Study ID
NCT02745080
Run by
Novartis Pharmaceuticals
People needed
853
Starts
2017-04-03
Expected to finish
2019-12-30
Last updated by the study team
2021-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.